Milan, Italy (May 20, 2022)

Today, MgShell, a MedTech company that aspires to inspire a change in ophthalmology by developing a magnesium-based drug delivery platform capable of reshaping patient care and enhancing treatment adherence for patients suffering from retinal diseases, announced its winning of the Brevetti+ grant promoted by Invitalia.

The contribution granted by Invitalia covers 80% of the company’s intellectual property valorization project that amounts to €93,500. Specifically, the contribution will enable the valorization of one of the patent applications of the company through the funding of preclinical development activities in accordance with the company’s development plan.

About MgShell:

MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.